Chronic neurogenic pain is responsible for changes in concentrations of biogenic amines in the brain in urokinase knockout mice with melanoma B16/F10

Автор: Frantsiyants Elena M., Bandovkina Valeriya A., Kaplieva Irina V., Surikova Ekaterina I., Neskubina Irina V., Cheryarina Natalia D., Pozdnyakova Viktoria V., Kit Oleg I.

Журнал: Cardiometry @cardiometry

Рубрика: Original research

Статья в выпуске: 17, 2020 года.

Бесплатный доступ

Our aim is to study special features of actions and effects of chronic neurogenic pain on concentrations of biogenic amines in the brain in tumor-bearing urokinase knockout mice (uPA). Materials and methods Our research work has been conducted in female/male mice line C57BL/6 (uPA+/+) n=48 and line C57BL/6-Plautm1.1Bug-ThisPlauGFDhu/GFDhu (uPA) -/-) n = 48 with targeted mutation of protein incapable of binding to receptor of the urokinase-type plasminogen activator, i.e. in the urokinase knockout (uPA) mice. The animals of each line have been divided into subgroups (n= 6) as follows: the intact animals, the chronic neurogenic pain mice (CNP), the mice with the growth of inoculated melanoma (B16/F10) and the mice with combination melanoma growth plus chronic neurogenic pain (B16/F10 + CNP). In 10% of the brain homogenates, with the use of standard analysis system method ELISA (Cusabio. China), we have determined concentrations of adrenaline (A), noradrenaline (NA), dopamine (DA), histamine, serotonin (5HT) and 5-hydroxyindoleacetic acid (5-HIAA). Obtained statistic data have been processed using the Statistica 10.0 package. Results The concentration of biogenic amines in the brain in the intact uPA-/- mice has been found to be higher than in the intact uPA+/+ animals, and the response to the growth of inoculatedmelanoma B16/F10 and CNP under single-factor action and combined-action variants depends both on the sex and the condition of the urokinase gene. In the uPA-/- female/male mice in response to the only CNP and the only B16/F10 growth the serotonergic system in the brain has been activated. In contrast thereto, in case of the melanoma growth against the CNP background, we have revealed a decrease in the level of 5HT, DA in the female/male mice and NA in the female animals. Conclusion One of the factors resulting in cancellation of the genetically determined inhibition of the growth of inoculated melanoma B16/F10 under its combination with developing CNP in the uPA-/- mice is suppression of their noradrenergic, serotonergic and dopaminergic systems, initially activated in the intact uPA-/- animals to compensate their urokinase deficit.

Еще

C57/b16 mice line, upa, brain biogenic amines, chronic neurogenic pain, inoculated melanoma b16/f10

Короткий адрес: https://sciup.org/148311476

IDR: 148311476   |   DOI: 10.12710/cardiometry.2020.17.49-57

Список литературы Chronic neurogenic pain is responsible for changes in concentrations of biogenic amines in the brain in urokinase knockout mice with melanoma B16/F10

  • Merino P, et al. Urokinase-type plasminogen ac¬tivator (uPA) binding to the uPA receptor (uPAR) promotes axonal regeneration in the central nervous system. J.Biol. Chem. 2017; 292 (7): 2741–53. DOI: 10.1074/jbc.M116.761650.
  • Merino P, et al. Urokinase-type plasminogen acti¬vator (uPA) promotes ezrin-mediated reorganization of the synaptic cytoskeleton in the ischemic brain. J Biol Chem. 2018 Jun 15;293(24):9234-9247. doi: 10.1074/jbc.RA118.002534.
  • Yepes M. Urokinase-type plasminogen activa¬tor is a modulator of synaptic plasticity in the cen¬tral nervous system: implications for neurorepair in the ischemic brain Neural Regen Res. 2020 Apr; 15(4): 620–624. Published online 2019 Oct 18. doi: 10.4103/1673-5374.266904
  • Kyyriäinen J, et al. Deficiency of urokinase-type plasminogen activator and its receptor affects social behavior and increases seizure susceptibility. Epi¬lepsy Res. 2019 Mar;151:67-74. doi: 10.1016/j.eplep-syres.2019.02.009.
  • Medcalf RL. Fibrinolysis: from blood to the brain. J Thromb Haemost. 2017 Nov;15(11):2089-2098. doi: 10.1111/jth.13849.
  • Yepes M The Plasminogen Activation System Pro¬motes Neurorepair in the Ischemic Brain Curr Drug Targets. 2019 Jul; 20(9): 953–959. doi: 10.2174/1389450120666181211144550
  • Rantalaa J, et al. Urokinase-type plasminogen ac¬tivator deficiency has little effect on seizure suscep-tibility and acquired epilepsy phenotype but reduces spontaneous exploration in mice Epilepsy & Behav¬ior. 2015; (42): 117-128 https://doi.org/10.1016/j.ye¬beh.2014.11.001
  • Carhart-Harris RL, Nutt DJ. Serotonin and brain function: a tale of two receptors. J Psychophar¬macol. 2017 Sep;31(9):1091-120. doi: 10.1177/ 0269881117725915
  • Ong WY, Stohler CS, Herr DR. Role of the Prefron¬tal Cortex in Pain Processing.Mol Neurobiol. 2019 Feb;56(2):1137-66. doi: 10.1007/s12035-018-1130-9.
  • Zhou W, et al. A neural circuit for comorbid de¬pressive symptoms in chronic pain. Nat Neurosci. 2019 Oct;22(10):1649-58. doi: 10.1038/s41593-019-0468-2.
  • Taylor BK, Westlund KN. The noradrenergic lo¬cus coeruleus as a chronic pain generator. J Neurosci Res. 2017 Jun;95(6):1336-46. doi: 10.1002/jnr.23956.
  • Ji NN, Kang J, Hua R, Zhang YM. Involvement of dopamine system in the regulation of the brain corti-cotropin-releasing hormone in paraventricular nucleus in a rat model of chronic visceral pain. Neurol Res. 2018 Aug;40(8):650-7. doi: 10.1080/01616412.2018.1460702.
  • Doan L, Manders T, Wang J. Neuroplasticity un¬derlying the comorbidity of pain and depression. Neural Plast. 2015;2015(2):504691.
  • Worm J, FalkenbergK, Olesen J. Histamine and migraine revisited: mechanisms and possible drug targets. J Headache Pain. 2019;20(1):30. Published online 2019 Mar 25. doi: 10.1186/s10194-019-0984-1
  • Nieto-Alamilla G, et al. The histamine H3 recep¬tor: structure, pharmacology, and function. Mol Phar-macol. 2016; 90:649–73. doi: 10.1124/mol.116.104752
  • Kilinc E, et al. Serotonergic mechanisms of tri¬geminal meningeal nociception: implications for mi¬graine pain. Neuropharmacology. 2017;116:160–73. doi: 10.1016/j.neuropharm.2016.12.024.
  • Bolam PJ, Ellender TJ. Histamine and the stria¬tum Neuropharmacology. 2016 Jul; 106: 74–84. doi: 10.1016/j.neuropharm.2015.08.013
  • Scammell TE, et al. Histamine: neural circuits and new medications Sleep. 2019 Jan; 42(1): zsy183. Pub-lished online 2018 Sep 18. doi: 10.1093/sleep/zsy183
  • Kit O. I., et al. Some mechanisms of increasing the malignancy of melanoma against the backgr.of chronic pain in female mice. Rus. jour. of pain. 2017;2(53):14-20. [in Russian]
  • Frantsiyants EM, et al. Effect of wildebeest knock¬out urokinase on melanoma growth in the experiment Siberian scientific medical journal.2019;39(4):62-70 DOI:10.15372/SSMJ20190408 [in Russian]
  • Kit OI, et al. Neurotransmitter systems of the brain of female mice in the dynamics of growth of malig-nant melanoma reproduced against the background of chronic pain. Pathogenesis. 2017;415(4):49-55. DOI: 10.5557/GM.2018.4.9749 [in Russian]
  • Elyazia Al Maamari, et al. Inhibition of urokinase plasminogen activator “uPA” activity alters ethanol consumption and conditioned place preference in mice Drug Des Devel Ther.2014;8:1391–403. Pub-lished online 2014 Sep 16. doi: 10.2147/DDDT.S68636
  • Zhang Y, et al. In vivo measurement of the dynam¬ics of norepinephrine in an olfactory bulb following ischemia-induced olfactory dysfunction and its re¬sponses to dexamethasone treatment. Analyst. 2018 Nov 7;143(21):5247-54. doi: 10.1039/c8an01300d
  • Becker JB, Chartoff E. Sex differences in neural mechanisms mediating reward and addiction. Neu-ropsychopharmacology. 2019 Jan;44(1):166-83. doi: 10.1038/s41386-018-0125-6
  • Rosen S, Ham B, Mogil JS. Sex differences in neuroimmunity and pain. J Neurosci Res. 2017 Jan 2;95(1-2):500-8. doi: 10.1002/jnr.23831.
  • Llorca-Torralba M, et al. Noradrenergic Locus Coeruleus pathways in pain modulation. Neurosci¬ence. 2016 Dec 3;338:93-113. doi: 10.1016/j.neurosci¬ence.2016.05.057.
  • Obata H. Analgesic Mechanisms of Antidepres¬sants for Neuropathic Pain. Int J Mol Sci. 2017 Nov 21;18(11):2483. doi: 10.3390/ijms18112483.
  • Fournier JC, et al. Antidepressant drug effects and depression severity: a patient-level meta-anal¬ysis. Journal of the American Medical Association. 2010;303(1):47–53. doi: 10.1001/jama.2009.1943.
  • Frantsiyants EM, et al. Effect of B16/F10 trans¬planted melanoma growth on the functioning of the hypothalamic-pituitary-adrenal and thyroid axes in male and female mice. News of higher educational institutions. North Caucasus region. Natural scienc¬es. 2017;3-2:118-24. [in Russian]
Еще
Статья научная